VUZE Medical to Showcase Next Generation Software-based Guidance System for Spine Surgery at NASS 2023 Following FDA Filing
VUZE Medical , a privately-held company aiming to transform intra-operative guidance in minimally invasive spinal interventions, has submitted a 510(k) filing with the U.S. Food and Drug Administration (FDA) for VUZE 2.0, its second generation VUZE System .
- VUZE Medical , a privately-held company aiming to transform intra-operative guidance in minimally invasive spinal interventions, has submitted a 510(k) filing with the U.S. Food and Drug Administration (FDA) for VUZE 2.0, its second generation VUZE System .
- The VUZE System is a software solution installed on an off-the-shelf PC.
- The VUZE System previously received U.S. FDA 510(k) clearance in 2022 and completed a successful first-in-human clinical trial in early 2023.
- “Our second generation aims to extend the operability of the VUZE System across a much larger percentage of operating rooms,” said David Tolkowsky, founder and CEO of VUZE Medical.